Non-valvular Atrial Fibrillation
56
4
7
32
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.4%
3 terminated out of 56 trials
91.4%
+4.9% vs benchmark
11%
6 trials in Phase 3/4
31%
10 of 32 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 32 completed trials
Clinical Trials (56)
An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Subjects With Non-Valvular Atrial Fibrillation
Watchman for Patients With Atrial Fibrillation Undergoing Transcatheter Mitral Valve Repair (WATCH-TMVR)
A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination
Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation
Study of the Effects of Anticoagulant Interruption Covered by Percutaneous Left Atrial Occlusion in Patients With Chronic Atrial Fibrillation and Radiation Cystitis at Risk of Bleeding
Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation
The CONFORMAL Early Feasibility Study
Amplatzer Amulet China Post Market Study (PMS)
Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
Safety and Efficacy of Apixaban in Very Old Geriatric Subjects (> 80 Years) With Atrial FIbrillation in a Prospective reAl World Study;
Non-antithrombotic Versus. Single Antiplatelet Therapy Following Left Atrial Appendage Closure
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China
Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
The Conformal Prague Study
Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong
Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
WAVECREST Post Market Clinical Follow-Up (PMCF) Study
First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder